Inhaled gene therapy in lung cancer: Proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1171-1194

  Zarogoulidis, Paul ^a,b   Darwiche, Kaid ^b   Hohenforst Schmidt, Wolfgang ^c   Huang, Haidong ^d   Li, Qiang ^d   Freitag, Lutz ^b   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

aerosol therapy; delivery systems; gene therapy; lung cancer; micro oncology; nanobiotechnology

Indexed keywords

ALPHA INTERFERON; APATITE; BETA INTERFERON; BEVACIZUMAB; CABOZANTINIB; CARBONIC ACID; CETUXIMAB; CRIZOTINIB; EVEROLIMUS; FICLATUZUMAB; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GOLD NANOPARTICLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MK 2461; NERATINIB; OSTEOPONTIN; PACLITAXEL; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; THROMBOSPONDIN 1; TIVANTINIB; TOPOTECAN; UNCLASSIFIED DRUG; VANDETANIB;

AEROSOL; ANGIOGENESIS; APOPTOSIS; BIOEQUIVALENCE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; DEACETYLATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOCYTOSIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; IONIC STRENGTH; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; MICROMETASTASIS; MOLECULAR WEIGHT; NANOBIOTECHNOLOGY; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PKA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECOMBINANT PLASMID; REVIEW; SURVIVAL RATE; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TRANSCRIPTION INITIATION; TRANSLATION INITIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VISCOSITY;

AEROSOLS; DISEASE-FREE SURVIVAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; NANOPARTICLES; NANOTECHNOLOGY; RESPIRATORY THERAPY;

EID: 84881286933     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.67     Document Type: Review

References (156)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61 (2), 69-90 (2011).
2. Novello S, Longo M, Levra MG. Toward therapies tailored to patient characteristics. J. Thorac. Oncol. 2 (Suppl. 5), S38-S41 (2007).
3. Zarogoulidis K, Papagiannis A, Ziogas E et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur. J. Cancer 33 (14), 2428-2431 (1997).
4. Viani GA, Boin AC, Ikeda VY, Vianna BS, Silva RS, Santanella F. Thirty years of prophylactic cranial irradiation in patients with small cell lung cancer: A meta-analysis of randomized clinical trials. J. Bras. Pneumol. 38 (3), 372-381 (2012).
5. Shepherd FA, Crowley J, Van Houtte P et al. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J. Thorac. Oncol. 2 (12), 1067-1077 (2007).
6. Zarogoulidis K, Eleftheriadou E, Kontakiotis T et al. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer 76 (1), 84-88 (2012).
7. Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res. 31 (10), 3193-3204 (2011).
8. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin. Lung Cancer 9 (2), 102-105 (2008).
9. Zhang D, Ochi N, Takigawa N et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 309 (2), 228-235 (2011).
10. Zarogoulidis P, Eleftheriadou E, Sapardanis I et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. N. Drugs 30 (4), 1628-1640 (2011).
11. Hasenpusch G, Pfeifer C, Aneja MK et al. Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS One 6 (6), e20760 (2011).
12. Jin H, Kim TH, Hwang SK et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther. 5 (4), 1041-1049 (2006).
13. Zarogoulidis P, Chatzaki E, Porpodis K et al. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int. J. Nanomed. 7, 1551-1572 (2012).
14. Porpodis K, Karanikas M, Zarogoulidis P et al. A case of typical pulmonary carcinoid tumor treated with bronchoscopic therapy followed by lobectomy. J. Multidiscip. Healthc. 5, 47-51 (2012).
15. Markman M. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 117 (2), 390; author reply 391 (2010).
16. Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E. Inhaled insulin: Too soon to be forgotten? J. Aerosol. Med. Pulm. Drug Deliv. 24 (5), 213-223 (2011).
17. Chen ZH, Kim HP, Ryter SW, Choi AM. Identifying targets for COPD treatment through gene expression analyses. Int. J. Chron. Obstruct. Pulmon. Dis. 3 (3), 359-370 (2008).
18. Chen X, Huang W, Wong BC et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomed. 7, 1139-1148 (2012).
19. Gautam A, Densmore CL, Waldrep JC. Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol. Ther. 2 (4), 318-323 (2000).
20. Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8 (9), 619-627 (2001).
21. Gautam A, Densmore CL, Golunski E, Xu B, Waldrep JC. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol. Ther. 3 (4), 551-556 (2001).
22. Lechmann S, Bykov V, Ali D et al. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 30 (29), 3633-3639 (2012).
23. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 129 (2), 211-215 (1984).
24. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 (6), 600-612 (2003).
25. Wilson AM, Dempsey OJ, Coutie WJ, Sims EJ, Lipworth BJ. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet 353 (9170), 2128 (1999).
26. Kendrick AH, Smith EC, Wilson RS. Selecting and using nebuliser equipment. Thorax 52 (Suppl. 2), S92-S101 (1997).
27. Clark AR. Understanding penetration index measurements and regional lung targeting. J. Aerosol Med. Pulm. Drug Deliv. 25 (4), 179-187 (2012).
28. Ayrton A, Morgan P. Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica 38 (7-8), 676-708 (2008).
29. van der Deen M, Marks H, Willemse BW et al. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch. 449 (6), 682-688 (2006).
30. van der Deen M, de Vries EG, Visserman H et al. Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. J. Biochem. Mol. Toxicol. 21 (5), 243-251 (2007).
31. Leclerc J, Courcot-Ngoubo Ngangue E, Cauffiez C et al. Xenobiotic metabolism and disposition in human lung: Transcript profiling in non-tumoral and tumoral tissues. Biochimie 93 (6), 1012-1027 (2011).
32. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 (6), 588-599 (2003).
33. Densmore CL. The re-emergence of aerosol gene delivery: A viable approach to lung cancer therapy. Curr. Cancer Drug Targets 3 (4), 275-286 (2003).
34. Davies JC, Alton EW. Airway gene therapy. Adv. Genet. 54, 291-314 (2005).
35. Zarogoulidis P, Kontakiotis T, Zarogoulidis K. Inhaled gene therapy in lung cancer: "as for the future, our task is not to foresee it, but to enable it". Ther. Deliv. 3 (8), 919-921 (2012).
36. Romano G. Current development of nonviral-mediated gene transfer. Drug News Perspect. 20 (4), 227-231 (2007).
37. Maestrelli P, Schlunssen V, Mason P, Sigsgaard T. Contribution of host factors and workplace exposure to the outcome of occupational asthma. Eur. Respir. Rev. 21 (124), 88-96 (2012).
38. Zarogoulidis P, Giraleli C, Karamanos NK. Inhaled chemotherapy in lung cancer: Safety concerns of nanocomplexes delivered. Ther. Deliv. 3 (9), 1021-1023 (2012).
39. Lee ER, Marshall J, Siegel CS et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7 (14), 1701-1717 (1996).
40. Densmore CL, Giddings TH, Waldrep JC, Kinsey BM, Knight V. Gene transfer by guanidinium-cholesterol: Dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J. Gene Med. 1 (4), 251-264 (1999).
41. Densmore CL, Orson FM, Xu B et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol. Ther. 1 (2), 180-188 (2000).
42. Stribling R, Brunette E, Liggitt D, Gaensler K, Debs R. Aerosol gene delivery in vivo. Proc. Natl Acad. Sci. USA 89 (23), 11277-11281 (1992).
43. Eastman SJ, Tousignant JD, Lukason MJ et al. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum. Gene Ther. 8 (3), 313-322 (1997).
44. Freimark BD, Blezinger HP, Florack VJ et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes. J. Immunol. 160 (9), 4580-4586 (1998).
45. Scheule RK, St George JA, Bagley RG et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8 (6), 689-707 (1997).
46. Alton EW, Stern M, Farley R et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial. Lancet 353 (9157), 947-954 (1999).
47. Kim TH, Kim SI, Akaike T, Cho CS. Synergistic effect of poly (ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes. J. Control. Release 105 (3), 354-366 (2005).
48. Gautam A, Waldrep JC, Orson FM, Kinsey BM, Xu B, Densmore CL. Topical gene therapy for pulmonary diseases with PEI-DNA aerosol complexes. Methods Mol. Med. 75, 561-572 (2003).
49. Gautam A, Waldrep JC, Kleinerman ES et al. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods Mol. Med. 75, 607-618 (2003).
50. Gautam A, Waldrep JC, Densmore CL. Aerosol gene therapy. Mol. Biotechnol. 23 (1), 51-60 (2003).
51. Gautam A, Densmore CL, Xu B, Waldrep JC. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol. Ther. 2 (1), 63-70 (2000).
52. Jere D, Xu CX, Arote R, Yun CH, Cho MH, Cho CS. Poly (b-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 29 (16), 2535-2547 (2008).
53. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 16 (12), 892-899 (2009).
54. Hwang SK, Jin H, Kwon JT et al. Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice. Gene Ther. 14 (18), 1353-1361 (2007).
55. Koshkina NV, Agoulnik IY, Melton SL, Densmore CL, Knight V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: Optimization of pulmonary delivery and retention. Mol. Ther. 8 (2), 249-254 (2003).
56. Davies LA, Mclachlan G, Sumner-Jones SG et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol. Ther. 16 (7), 1283-1290 (2008).
57. Tehrani AM, Hwang SK, Kim TH et al. Aerosol delivery of Akt controls protein translation in the lungs of dual luciferase reporter mice. Gene Ther. 14 (5), 451-458 (2007).
58. Minai-Tehrani A, Park YC, Hwang SK et al. Aerosol delivery of kinase-deficient Akt1 attenuates Clara cell injury induced by naphthalene in the lungs of dual luciferase mice. J. Vet. Sci. 12 (4), 309-317 (2011).
59. Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin. Cancer Res. 13 (16), 4900-4908 (2007).
60. Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9 (1), 28-36 (2002).
61. Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8 (9), 619-627 (2001).
62. Xu CX, Jere D, Jin H et al. Poly (ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am. J. Respir. Crit. Care Med. 178 (1), 60-73 (2008).
63. Gautam A, Densmore CL, Waldrep JC. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene Ther. 8 (3), 254-257 (2001).
64. Kim HW, Park IK, Cho CS et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res. 64 (21), 7971-7976 (2004).
65. Lesina E, Dames P, Flemmer A et al. CpG-free plasmid DNA prevents deterioration of pulmonary function in mice. Eur. J. Pharm. Biopharm. 74 (3), 427-434 (2010).
66. Lesina E, Dames P, Rudolph C. The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. J. Control. Release 143 (2), 243-250 (2010).
67. Ahn CH, Chae SY, Bae YH, Kim SW. Biodegradable poly (ethylenimine) for plasmid DNA delivery. J. Control. Release 80 (1-3), 273-282 (2002).
68. Gautam A, Densmore CL, Waldrep JC. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene Ther. 8 (3), 254-257 (2001).
69. Erbacher P, Bettinger T, Brion E et al. Genuine DNA/polyethylenimine (PEI) complexes improve transfection properties and cell survival. J. Drug Target 12 (4), 223-236 (2004).
70. Singla AK, Chawla M. Chitosan: Some pharmaceutical and biological aspects - an update. J. Pharm. Pharmacol. 53 (8), 1047-1067 (2001).
71. Huang YC, Vieira A, Huang KL, Yeh MK, Chiang CH. Pulmonary inflammation caused by chitosan microparticles. J. Biomed. Mater. Res. A 75 (2), 283-287 (2005).
72. Mao S, Shuai X, Unger F, Simon M, Bi D, Kissel T. The depolymerization of chitosan: Effects on physicochemical and biological properties. Int. J. Pharm. 281 (1-2), 45-54 (2004).
73. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon- b gene complex powder for inhalation treatment of lung metastasis in mice. J. Control. Release 150 (2), 187-195 (2011).
74. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed. 1 (2), 117-128 (2006).
75. Jin H, Kim TH, Hwang SK et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther. 5 (4), 1041-1049 (2006).
76. Koping-Hoggard M, Tubulekas I, Guan H et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8 (14), 1108-1121 (2001).
77. Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J. Clin. Invest. 97 (4), 1102-1110 (1996).
78. Arndt CA, Koshkina NV, Inwards CY et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clin. Cancer Res. 16 (15), 4024-4030 (2010).
79. Xing Z, Tremblay GM, Sime PJ, Gauldie J. Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-b 1 and myofibroblast accumulation. Am. J. Pathol. 150 (1), 59-66 (1997).
80. Xing Z, Braciak T, Ohkawara Y et al. Gene transfer for cytokine functional studies in the lung: The multifunctional role of GM-CSF in pulmonary inflammation. J. Leukoc. Biol. 59 (4), 481-488 (1996).
81. Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5 (9), 2316-2323 (1999).
82. Richard-Fiardo P, Cambien B, Pradelli E et al. Effect of fractalkine-Fc delivery in experimental lung metastasis using DNA/704 nanospheres. Cancer Gene Ther. 18 (11), 761-772 (2011).
83. Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ. DNA damage and p53-mediated cell cycle arrest: A reevaluation. Proc. Natl Acad. Sci. USA 93 (26), 15209-15214 (1996).
84. Lawlor MA, Alessi DR PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114 (Pt 16), 2903-2910 (2001).
85. Massion PP, Taflan PM, Shyr Y et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170 (10), 1088-1094 (2004).
86. Brambilla E, Brambilla C. p53 and lung cancer. Pathol. Biol. (Paris) 45 (10), 852-863 (1997).
87. Fan J, Bertino Jr. Modulation of cisplatinum cytotoxicity by p53: Effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol. 56 (5), 966-972 (1999).
88. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91 (7), 620-625 (1999).
89. Goetsch L, Gonzalez A, Leger O et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113 (2), 316-328 (2005).
90. Dong AQ, Kong MJ, Ma ZY, Qian JF, Xu XH. Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol. Int. 31 (5), 500-507 (2007).
91. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92 (12), 4491-4508 (1998).
92. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin. Cancer Res. 2 (4), 721-734 (1996).
93. Khanna C, Waldrep JC, Anderson PM et al. Nebulized interleukin 2 liposomes: Aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 49 (10), 960-971 (1997).
94. Sznol M, Dutcher JP, Atkins MB et al. Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treat. Rev. 16 (Suppl. A), S29-S38 (1989).
95. Huland E, Heinzer H, Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon b in patients with pulmonary metastatic renal-cell carcinoma: Effectiveness and toxicity of mainly local treatment. J. Cancer Res. Clin. Oncol. 120 (4), 221-228 (1994).
96. Rosenberg SA. Immunotherapy and gene. Therapy of cancer. Cancer Res. 51 (Suppl. 18), S5074-S5079 (1991).
97. Kasid A, Morecki S, Aebersold P et al. Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc. Natl Acad. Sci. USA 87 (1), 473-477 (1990).
98. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50 (24), 7820-7825 (1990).
99. Asher AL, Mule JJ, Kasid A et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146 (9), 3227-3234 (1991).
100. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172 (4), 1217-1224 (1990).
101. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann. NY Acad. Sci. 760, 299-301 (1995).
102. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of Ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54 (3), 832-837 (1994).
103. Yu KN, Minai-Tehrani A, Chang SH et al. Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One 5 (12), e15623 (2010).
104. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J. Clin. Oncol. 17 (8), 2334-2340 (1999).
105. Kanehira T, Tani T, Takagi T, Nakano Y, Howard EF, Tamura M. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: Involvement of transforming growth factor-b-dependent cell growth attenuation. Cancer Res. 65 (17), 7660-7665 (2005).
106. Antus B, Mucsi I, Rosivall L. Apoptosis induction and inhibition of cellular proliferation by angiotensin II: Possible implication and perspectives. Acta Physiol. 87 (1), 5-24 (2000).
107. Kawabata A, Baoum A, Ohta N et al. Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 72 (8), 2057-2067 (2012).
108. Uchida S, Itaka K, Chen Q et al. PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol. Ther. 20 (6), 1196-1203 (2012).
109. Brissault B, Kichler A, Leborgne C et al. Synthesis, characterization, and gene transfer application of poly (ethylene glycol-b-ethylenimine) with high molar mass polyamine block. Biomacromolecules 7 (10), 2863-2870 (2006).
110. Fan W, Wu X, Ding B et al. Degradable gene delivery systems based on Pluronics-modified low-molecular-weight polyethylenimine: Preparation, characterization, intracellular trafficking, and cellular distribution. Int. J. Nanomed. 7, 1127-1138 (2012).
111. Jiang Z, Sun C, Yin Z et al. Comparison of two kinds of nanomedicine for targeted gene therapy: Premodified or postmodified gene delivery systems. Int. J. Nanomed. 7, 2019-2031 (2012).
112. Zeng Q, Han J, Zhao D, Gong T, Zhang Z, Sun X. Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int. J. Nanomed. 7, 985-997 (2012).
113. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. Cross-linked small polyethylenimines: While still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm. Res. 22 (3), 373-380 (2005).
114. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 (3), 329-347 (2003).
115. Wang YQ, Su J, Wu F et al. Biscarbamate cross-linked polyethylenimine derivative with low molecular weight, low cytotoxicity, and high efficiency for gene delivery. Int. J. Nanomed. 7, 693-704 (2012).
116. Cheang TY, Tang B, Xu AW et al. Promising plasmid DNA vector based on APTES-modified silica nanoparticles. Int. J. Nanomed. 7, 1061-1067 (2012).
117. Burns AA, Vider J, Ow H et al Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 9 (1), 442-448 (2009).
118. Schughart K, Bischoff R, Rasmussen UB et al. Solvoplex: A new type of synthetic vector for intrapulmonary gene delivery. Hum Gene Ther. 10 (18), 2891-2905 (1999).
119. Shi S, Zhu X, Guo Q et al. Self-assembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: Synthesis and characterization in vitro. Int. J. Nanomed. 7, 1749-1759 (2012).
120. Ma W, Chen M, Kaushal S et al. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int. J. Nanomed. 7, 1475-1487 (2012).
121. Hossain S, Stanislaus A, Chua MJ et al. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J. Control. Release 147 (1), 101-108 (2010).
122. Chowdhury EH, Akaike T. High performance DNA nano-carriers of carbonate apatite: Multiple factors in regulation of particle synthesis and transfection efficiency. Int. J. Nanomed. 2 (1), 101-106 (2007).
123. Li HY, Seville PC, Williamson IJ, Birchall JC. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J. Gene Med. 7 (3), 343-353 (2005).
124. Li HY, Neill H, Innocent R, Seville P, Williamson I, Birchall JC. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J. Drug Target 11 (7), 425-432 (2003).
125. Puvanakrishnan P, Park J, Chatterjee D, Krishnan S, Tunnell JW. In vivo tumor targeting of gold nanoparticles: Effect of particle type and dosing strategy. Int. J. Nanomed. 7, 1251-1258 (2012).
126. Hirsch LR, Stafford RJ, Bankson JA et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA 100 (23), 13549-13554 (2003).
127. Loo C, Lowery A, Halas N, West J, Drezek R Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5 (4), 709-711 (2005).
128. Allison R, Moghissi K, Downie G, Dixon K. Photodynamic therapy (PDT) for lung cancer. Photodiagnosis Photodyn. Ther. 8 (3), 231-239 (2011).
129. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41 (2), 147-162 (2000).
130. Zhong Z, Wan Y, Han J, Shi S, Zhang Z, Sun X. Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate modified anionic liposomes. Int. J. Nanomed. 6, 1083-1093 (2011).
131. Li P, Liu D, Miao L et al. A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery. Int. J. Nanomed. 7, 925-939 (2012).
132. Schule S, Friess W, Bechtold-Peters K, Garidel P. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations. Eur. J. Pharm. Biopharm. 65 (1), 1-9 (2007).
133. Maillet A, Congy-Jolivet N, Le Guellec S et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm. Res. 25 (6), 1318-1326 (2008).
134. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102 (21), 7665-7670 (2005).
135. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther. 7 (2), 262-268 (2000).
136. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (1), 327-337 (2003).
137. Blumenschein G Jr. Sorafenib in lung cancer: Clinical developments and future directions. J. Thorac. Oncol. 3 (6 Suppl. 2), S124-S127 (2008).
138. Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, Phase 3 trial. Lancet Oncol. 11 (7), 619-626 (2010).
139. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 (9), 4408-4417 (2007).
140. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (7153), 561-566 (2007).
141. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8 (8), 627-644 (2009).
142. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14 (6), 559-570 (2009).
143. Kanwar JR, Palmano KP, Sun X et al. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol. Cell Biol. 86 (3), 277-288 (2008).
144. Takeuchi T, Jyonotsuka T, Kamemori N et al. Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp. Physiol. 91 (6), 1033-1040 (2006).
145. Gan N, Jin H, Li T, Zheng L. Fe (3)O (4)/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein. Int. J. Nanomed. 6, 3259-3269 (2011).
146. Liu L, Ge D, Ma L et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J. Thorac. Oncol. 7 (7), 1091-1100 (2012).
147. West J, Rodman DM. Gene therapy for pulmonary diseases. Chest 119 (2), 613-617 (2001).
148. Hamilton KO, Yazdanian MA, Audus KL. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and b-ligands. Int. J. Pharm. 228 (1-2), 171-179 (2001).
149. Hamilton KO, Backstrom G, Yazdanian MA, Audus KL. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci. 90 (5), 647-658 (2001).
150. Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106 (6), 1382-1388 (2006).
151. Kooijmans SA, Vader P, Van Dommelen SM, Van Solinge WW, Schiffelers RM. Exosome mimetics: A novel class of drug delivery systems. Int. J. Nanomed. 7, 1525-1541 (2012).
152. Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Curr. Cancer Drug Targets 3 (4), 239-250 (2003).
153. Li Q, Kawamura K, Okamoto S et al. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br. J. Cancer 105 (9), 1302-1312 (2011).
154. Sanvito L, Tomita A, Chihara N et al. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-b and interferon-b combined with low-dose oral steroids. J. Neuroimmunol. 236 (1-2), 111-117 (2011).
155. Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 9 (15), 2207-2222 (1998).
156. Zarogouldis P, Karamanos NK, Porpodis K et al. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int. J. Mol. Sci. 13 (9), 10828-10862 (2012).